Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

被引：35

作者：

Lorusso, D. ^{[3
]}

Scambia, G. ^{[3
]}

Amadio, G. ^{[3
]}

di Legge, A. ^{[3
]}

Pietragalla, A. ^{[3
]}

De Vincenzo, R. ^{[3
]}

Masciullo, V. ^{[3
]}

Di Stefano, M. ^{[3
]}

Mangili, G. ^{[5
]}

Citterio, G. ^{[4
]}

Mantori, M. ^{[1
]}

Lambiase, A. ^{[1
]}

Bordignon, C. ^{[1
,2
]}

机构：

[1] MolMed, Milan, Italy

[2] Univ Vita Salute San Raffaele, I-20132 Milan, Italy

[3] Univ Cattolica Sacro Cuore, Dept Gynecol Oncol, Rome, Italy

[4] Ist Sci San Raffaele, Dept Oncol, I-20132 Milan, Italy

[5] Ist Sci San Raffaele, Dept Gynecol Oncol, I-20132 Milan, Italy

来源：

BRITISH JOURNAL OF CANCER | 2012年 / 107卷 / 01期

关键词：

NGR-hTNF; vascular targeting agent; doxorubicin; ovarian cancer; TUMOR-NECROSIS-FACTOR; PEGYLATED LIPOSOMAL DOXORUBICIN; VASCULAR-TARGETING AGENT; ANTITUMOR-ACTIVITY; DRUG PENETRATION; TNF-ALPHA; T-CELLS; GEMCITABINE; TRIAL; ENHANCEMENT;

D O I：

10.1038/bjc.2012.233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: The NGR-hTNF (asparagine-glycine-arginine-human tumour necrosis factor) is able to promote antitumour immune responses and to improve the intratumoural doxorubicin uptake by selectively damaging tumour blood vessels. METHODS: Patients progressing after >= 1 platinum/taxane-based regimen received NGR-hTNF 0.8 mu g m(-2) and doxorubicin 60 mg m(-2) every 3 weeks. Primary endpoint was a Response Evaluation Criteria in Solid Tumors-defined response rate with a target of more than 6 out of 37 responding patients. RESULTS: A total of 37 patients with platinum-free interval lower than 6 months (PFI < 6; n = 25), or between 6 and 12 months (PFI = 6-12; n = 12) were enrolled. Median baseline peripheral blood lymphocyte count (PBLC) was 1.6 per ml (interquartile range, 1.2-2.1). In all, 18 patients (49%) received more than 6 cycles. Febrile neutropaenia was registered in one patient (3%). Among 35 assessable patients, 8 (23%; 95% CI 12-39%) had partial response (2 with PFI < 6; 6 with PFI = 6-12) and 15 (43%) had stable disease (10 with PFI < 6; 5 with PFI = 6-12). Median progression-free survival (PFS) was 5.0 months for all patients, 3.8 months for patients with PFI < 6, and 7.8 months for patients with PFI = 6-12. Median overall survival (OS) was 17.0 months. Patients with baseline PBLC higher than the first quartile had improved PFS (P = 0.01) and OS (P = 0.001). CONCLUSION: Tolerability and activity of this combination warrant further randomised testing in patients with PFI < 6. The role of PBLC as a blood-based biomarker deserves further investigation. British Journal of Cancer (2012) 107, 37-42. doi:10.1038/bjc.2012.233 www.bjcancer.com Published online 29 May 2012 (C) 2012 Cancer Research UK

引用

页码：37 / 42

页数：6

共 50 条

[21] PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS
Zucali, P. A.
Santoro, A.
Simonelli, M.
De Vincenzo, F.
Lorenzi, E.
Rimassa, L.
Balzarini, L.
Quagliuolo, V.
Lambiase, A.
Bordignon, C.
ANNALS OF ONCOLOGY, 2010, 21 : 173 - 173
[22] Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors.
Zucali, P. A.
Simonelli, M.
De Vincenzo, F.
Lorenzi, E.
Rimassa, L.
Balzarini, L.
Quagliuolo, V.
Lambiase, A.
Bordignon, C.
Santoro, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[23] Phase I and Pharmacodynamic Study of High-dose NGR-hTNF in Patients With Refractory Solid Tumours
Zucali, P. A.
Santoro, A.
Simonelli, M.
De Vincenzo, F.
Lorenzi, E.
Rimassa, L.
Balzarini, L.
Quagliuolo, V.
Lambiase, A.
Bordignon, C.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S145 - S146
[24] Two doses of NGR-hTNF combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens: A phase II study
Di Benedetto, M.
Bennicelli, E.
Andretta, V.
Pessino, A.
Guglielmi, A.
Sciallero, M. S.
Sobrero, A. F.
Fornarini, G.
Lambiase, A.
Bordignon, C.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[25] Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours
Zucali, P. A.
Simonelli, M.
De Vincenzo, F.
Lorenzi, E.
Perrino, M.
Bertossi, M.
Finotto, R.
Naimo, S.
Balzarini, L.
Bonifacio, C.
Timofeeva, I.
Rossoni, G.
Mazzola, G.
Lambiase, A.
Bordignon, C.
Santoro, A.
BRITISH JOURNAL OF CANCER, 2013, 108 (01) : 58 - 63
[26] Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC).
Gregorc, Vanesa
Zilembo, Nicoletta
Grossi, Francesco
De Pas, Tommaso M.
Rossoni, Gilda
Pietrantonio, Filippo
Rijavec, Erika
Citterio, Giovanni
Lambiase, Antonio
Bordignon, Claudio
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[27] Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors.
Simonelli, M.
Santoro, A.
Zucali, P. A.
Rimassa, L.
De Vincenzo, F.
Pressiani, T.
Tronconi, M. C.
Carnaghi, C.
Lambiase, A.
Bordignon, C.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[28] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC)
Santoro, A.
Citterio, G.
Pressiani, T.
De Braud, F. G.
Gregorc, V.
Rossoni, G.
Donadoni, G.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[29] NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study
Gregorc, V.
Ceresoli, G. L.
Zucali, P. A.
De Braud, F. G.
Bajetta, E.
Santoro, A.
Vigano, M. G.
Cappio, F. Caligaris
Lambiase, A.
Bordignon, C.
EJC SUPPLEMENTS, 2009, 7 (02): : 509 - 509
[30] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM)
Gregorc, V.
Ceresoli, G. L.
Zucali, P. A.
De Braud, F. G.
Bajetta, E.
Santoro, A.
Vigano, M. G.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →